Free Trial
NASDAQ:TLSA

Tiziana Life Sciences (TLSA) Stock Price, News & Analysis

Tiziana Life Sciences logo
$0.95 -0.02 (-2.06%)
(As of 11/22/2024 ET)

About Tiziana Life Sciences Stock (NASDAQ:TLSA)

Key Stats

Today's Range
$0.94
$1.00
50-Day Range
$0.85
$1.18
52-Week Range
$0.41
$1.74
Volume
101,519 shs
Average Volume
417,277 shs
Market Capitalization
$100.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Tiziana Life Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
11th Percentile Overall Score

TLSA MarketRank™: 

Tiziana Life Sciences scored higher than 11% of companies evaluated by MarketBeat, and ranked 917th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Tiziana Life Sciences.

  • Price to Book Value per Share Ratio

    Tiziana Life Sciences has a P/B Ratio of 19.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.37% of the float of Tiziana Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Tiziana Life Sciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tiziana Life Sciences has recently increased by 350.47%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Tiziana Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Tiziana Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.37% of the float of Tiziana Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Tiziana Life Sciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Tiziana Life Sciences has recently increased by 350.47%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Tiziana Life Sciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Tiziana Life Sciences this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for TLSA on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Tiziana Life Sciences' insider trading history.
Receive TLSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TLSA Stock News Headlines

Tiziana Life Sciences secures grant for ALS trial
JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
See More Headlines

TLSA Stock Analysis - Frequently Asked Questions

Tiziana Life Sciences' stock was trading at $0.56 at the start of the year. Since then, TLSA stock has increased by 70.0% and is now trading at $0.9522.
View the best growth stocks for 2024 here
.

Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

Tiziana Life Sciences' top institutional investors include Zhang Financial LLC (0.07%).

Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO) and Pfizer (PFE).

Company Calendar

Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TLSA
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.05 per share

Miscellaneous

Free Float
63,427,000
Market Cap
$100.36 million
Optionable
Optionable
Beta
0.63
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:TLSA) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners